ArticleBMJ public health2025

Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective.

Sara Wilhelmien Quist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.